Pharmaceuticals Global On demand · 24-48h

Global Radiopharmaceutical Transport Service Market Strategic Research Report

Global Radiopharmaceutical Transport Service Market Strategi…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Radiopharmaceutical Transport Service Market
$1.55B2025
5.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Short-half-life Radionuclide Transport, Long-half-life Radionuclide Transport

By Application: Radiopharmaceutical Manufacturers, Hospitals and Medical Institutions, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: AirNet II, Circle Express, Life Couriers, MNX Global Logistics, Kalitta Charters, Perlamar Ltd, Isotopes, Global Airfreight International, Ameriflight, SWAN Isotopen AG, Medi-Ops, Crisago, Yantai Dalong Logistics Co., Ltd., Sinotau Pharmaceutical Group, Ichimiya Transport, Transnuclear, SK Group

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 140 pages
Market size 2025
$1.55B
Billion USD
Forecast CAGR
5.4%
2025-2032
Forecast 2032
$2.2B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Radiopharmaceutical Transport Service market size is predicted to grow from US$ 1,553 million in 2025 to US$ 2,229 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Radiopharmaceutical transport service refers to the entire logistics process of safely and compliantly transporting radiopharmaceuticals containing radioisotopes used in nuclear medicine diagnosis or treatment from production sites to medical institutions, diagnostic centers, or patient usage locations. This transport process has extremely high requirements for time sensitivity, radiation protection, safety shielding, packaging compliance, and temperature control. It must strictly comply with the relevant regulations of the International Atomic Energy Agency (IAEA) and national nuclear safety regulatory authorities to ensure that radiation leakage is prevented during transport, personnel exposure is avoided, and the activity and efficacy of the drugs are guaranteed.

With the rapid development of nuclear medicine in tumor diagnosis and targeted therapy, the demand for radiopharmaceuticals continues to grow, driving the transport market towards specialization, refinement, and high safety standards. In the future, the expanded application of short-half-life isotopes will further strengthen the "just-in-time delivery + regionalized production + distributed supply chain" model, placing higher demands on the timeliness and reliability of the transport network. At the same time, automated shielded transport containers, intelligent tracking systems, unmanned transport, and integrated cold chain and radiation monitoring technologies will be rapidly adopted. Overall, the sector will maintain high growth as the precision medicine and radiopharmaceutical industries expand, but it will also continue to be constrained by strict regulation and high barriers to entry.

This report presents a comprehensive overview of the global Radiopharmaceutical Transport Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Short-half-life Radionuclide Transport
  • Long-half-life Radionuclide Transport

Segment by Transportation Methods

  • Road Transport
  • Air Transport
  • Rail Transport
  • Multimodal Transport

Segment by Environmental Requirements

  • Ambient Temperature Transport
  • Cold Chain Transport

Segment by Application

  • Radiopharmaceutical Manufacturers
  • Hospitals and Medical Institutions
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Radiopharmaceutical Transport Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Radiopharmaceutical Manufacturers, Hospitals and Medical Institutions, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Radiopharmaceutical Transport Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.55B
2025
Forecast
$2.2B
2032
CAGR
5.4%
2025–2032
Régions
5
global
Key companies
AirNet IICircle ExpressLife CouriersMNX Global LogisticsKalitta ChartersPerlamar LtdIsotopesGlobal Airfreight International
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Short-half-life Radionuclide TransportLong-half-life Radionuclide Transport
By Application
Radiopharmaceutical ManufacturersHospitals and Medical InstitutionsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Short-half-life Radionuclide Transport
  • 3.1.3 Long-half-life Radionuclide Transport
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Radiopharmaceutical Manufacturers
  • 4.1.3 Hospitals and Medical Institutions
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 AirNet II
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Circle Express
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Life Couriers
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 MNX Global Logistics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Kalitta Charters
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Perlamar Ltd
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Isotopes
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Global Airfreight International
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Ameriflight
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 SWAN Isotopen AG
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Medi-Ops
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Crisago
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Yantai Dalong Logistics Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Sinotau Pharmaceutical Group
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Ichimiya Transport
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Transnuclear
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 SK Group
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Radiopharmaceutical Transport Service market?
The global Radiopharmaceutical Transport Service market is estimated at US$ 1.55 billion in 2025 (base year) and is projected to reach US$ 2.23 billion by 2032.
What is the forecast CAGR for the Radiopharmaceutical Transport Service market?
The market is expected to grow at a CAGR of 5.4% from 2026 to 2032, expanding from US$ 1.55 billion in 2025 to US$ 2.23 billion in 2032, roughly 1.4 times its base-year value.
What is Radiopharmaceutical Transport Service?
Radiopharmaceutical transport service refers to the entire logistics process of safely and compliantly transporting radiopharmaceuticals containing radioisotopes used in nuclear medicine diagnosis or treatment from production sites to medical institutions, diagnostic centers, or patient usage locations. This transport process has extremely high requirements for time sensitivity, radiation protection, safety shielding, packaging compliance, and temperature control.
How is the Radiopharmaceutical Transport Service market segmented by type?
By type, the market is segmented into Short-half-life Radionuclide Transport and Long-half-life Radionuclide Transport.
What are the key applications of Radiopharmaceutical Transport Service?
Key applications covered include Radiopharmaceutical Manufacturers, Hospitals and Medical Institutions and Others.
Which companies are profiled in the Radiopharmaceutical Transport Service market report?
Key players profiled include AirNet II, Circle Express, Life Couriers, MNX Global Logistics, Kalitta Charters, Perlamar Ltd, Isotopes and Global Airfreight International, among 17 companies covered in total.
What geographies does the Radiopharmaceutical Transport Service market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Radiopharmaceutical Transport Service?
With the rapid development of nuclear medicine in tumor diagnosis and targeted therapy, the demand for radiopharmaceuticals continues to grow, driving the transport market towards specialization, refinement, and high safety standards.
What are the main risks and barriers in the Radiopharmaceutical Transport Service market?
Overall, the sector will maintain high growth as the precision medicine and radiopharmaceutical industries expand, but it will also continue to be constrained by strict regulation and high barriers to entry.
Who should buy the Radiopharmaceutical Transport Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Radiopharmaceutical Manufacturers, Hospitals and Medical Institutions and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Radiopharmaceutical Transport Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.